Staff Profile

Qualifications

Fellow of the Higher Education Academy (FHEA)

PhD Molecular Biology of Cancer, Newcastle University

BSc Biomedical Sciences, Newcastle University (First class)

Roles & Responsibilities

COST Action CA17138 EUROGRAFT Management Committee

COST Action CA17138 EUROGRAFT Science Communication Manager

Board Member (Science Communication): UK Society for Extracellular Vesicles (UKEV)

EDI Committee: Translational and Clinical Research Institute, Newcastle University

Editorial Positions

Review Editor: Frontiers in Immunology, Alloimmunity and Transplantation.

Editorial Board: International Journal of Immunology.

Guest Associate Editor: Frontiers Research Topic - New biomarkers in haematological disease

Awards

Wellcome Trust Translational Partnership – Translational Explorer Training Programme.

COST Association Scholarship - Cross-Cutting Activity in Science Communication,

Pathological Society Meeting Bursary – ISEV Annual Meeting, Barcelona. May 2018.

NanoString - RNA:Protein Panel International competition awardee.

Affymetrix - Tumour Profiling International competition awardee.

British Council Researcher Links Scholarship

Life Technologies - Ion Torrent™ Transcriptome Profiling International competition awardee

NanoString - PanCancer Panel Cancer Pathways International competition awardee.

Wellcome Trust - Advanced Course on Next Generation Sequencing Training Scholarship

First Poster Prize, EuroSciCon Meeting – Biomarker Discovery: Driving Technologies.

Newcastle University Graduate School Award – organization of NE Postgraduate Conference.

Websites

Google Scholar

ORCID

Loop

@RECrossland

Current Research

My research interests lie in the multi-disciplinary role of extracellular vesicles (EV) and their molecular cargo in disease pathology, as novel biomarkers for diagnosis and prognosis, and as potential therapeutic targets, particularly in relation to immune-mediated inflammatory diseases (IMID) and rare disease. I have a current focus on acute & chronic graft versus host disease (GvHD) as a model system, where I aim to:

     • Identify EV biomarkers of GvHD/IMID

     • Investigate the pathophysiological role of EVs in GvHD and immunotherapy

     • Investigate the action of MSC-EVs as a GvHD therapeutic

Extracellular Vesicles

Extracellular vesicles (EVs) have attracted excitement in the scientific community due to their novel role in intercellular communication. These cell-derived nanoparticles mediate local and systemic cellular communication by transferring their genetic and proteomic cargo to recipient cells, thus, reprogramming target cells and regulating normal physiological processes and pathological conditions. EVs are present in biofluids, where they deliver systemic communication, demonstrating enticing promise for ‘Liquid Biopsies’ in cancer, autoimmune and cardiovascular disease. EVs are released by immune cells and can act as antigen-presenting vesicles, stimulate antitumoral immune responses or induce tolerogenic effects to suppress inflammation. The role of EVs in the pathophysiology of immunological disorders is an exciting field for research, and these potent genetic information agents offer translatable and cross-disciplinary importance as potential therapeutic targets, informative biological agents, predictive biomarkers, & potential indicators of immunotherapeutic response. More information about EV research in the UK can be found by visiting the UK Society for Extracellular Vesicles: https://www.ukev.org.uk/

Active Projects

Mechanisms of action of ECP therapy for GvHD, focusing on the role of EV-derived microRNAs.

The aim of this project is to investigate the circulatory EV microRNA profiles post-HSCT in GvHD patients receiving ECP-therapy. As ECP is safe to administer with few significant adverse effects, it has the potential for earlier use in the post-HSCT treatment of GvHD. Thus, further understanding the molecular mechanisms of ECP action, including EV microRNAs, may justify more timely use in clinical practice, as well as identify biomarkers for using ECP as first line or pre-emptive GvHD therapy.

EV-derived microRNAs as biomarkers for GvHD onset, response to therapy and clinical outcome.

This project aims to assess circulatory microRNA expression profiles in patients with GvHD at sequential time points, in order to identify EV-microRNA signature biomarkers for prospective diagnosis, prognosis, and disease stratification to drive personalised medicine strategies.

Mechanism of action of EVs as a therapeutic for GvHD.

The aim of this project is to elucidate the therapeutic efficacy and mechanistic action of EVs in GvHD target organs. We are investigating the molecular mechanisms of action of NK-EVs and their active microRNA content in the context of GvHD. In collaboration with Prof. M. Inngjerdingen (Oslo University), will can use a validated GvHD rat model to perform digital spatial profiling of global immune response and T-cell activation in GvHD target tissues, in combination with full profiling of the EV molecular cargo, in response to EV therapy.

Current Collaborations

1. Acute exercise extracellular vesicle release and content (Dr S. Orange, Newcastle University).

2. Molecular profiling of autologous serum treatment for ocular GvHD (Dr. I. Bojanic, University Hospital Zagreb).

3. Germline genetic biomarkers of chronic GvHD (Prof. J. Partanen, Finnish Blood Transfusion Service).

4. MicroRNA profiling of gastric aGvHD (Prof. E. Holler, Regensburg University).

5. MicroRNA profiling of innate lymphoid cells in aGvHD (Prof. M. Inngjerdingen, Oslo University).

6. ECP in the treatment of chronic lung allograft dysfunction (Profs. A Fisher & A Gennery, Newcastle University).

7. Serum microRNA biomarkers for chronic GvHD (Prof. K Bogunia-Kubik, Warsaw University).

8. Osteoarthritis and rheumatoid arthritis EV microRNA profiling (Dr. A Pratt, Newcastle University).

9. The effect of osteoarthritis MSC-EV on chondrogenesis (Dr X. Wang, Newcastle University).

Active funding

1. Wellcome Trust Translational Partnership

    Funder: Wellcome Trust. PI: Dr R. Crossland

2. ECP in the treatment of Chronic Lung Allograft Dysfunction (E-CLAD UK)

    Funder: The Bubble Foundation. PI: Dr A. Gennery. COI: Dr R. Crossland

3. EV Molecular Profiles in relation to ECP Response in patients with cGvHD

    Funder: Newcastle Hospitals NHS Charity. PI: Prof. M. Collin. COI: Dr R. Crossland

4. Investigating EV Molecular Profiles in relation to ECP response in GvHD patients

    Funder: Mallinckrodt. PI: Dr R. Crossland. COI: Prof. M Collin.

5. Serum EV microRNA profiles in relation to molecular pathology and ECP response in GvHD

    Funder: The Pathological Society of Great Britain. PI: Dr R Crossland. COI: Prof. M Collin.

6. Engineering Exosomes as NanoVehicles for Cancer Therapy

    Funder: Research Council Norway. PI: Prof. Marit Inngjerdingen. COI: Dr R Crossland

Collaborative links with Industry

Wellcome Trust Translational Explorer Programme, in partnership with Alcyomics Ltd.

Memberships

The UK Society for Extracellular Vesicles (UKEV)

The International Society for Extracellular Vesicles (ISEV)

The Pathological Society of Great Britain

UK Photopheresis Society

PhD

Mr Steven Bolton (current)

Thesis: Extracorporeal Photopheresis in the treatment of Chronic Lung Allograft Dysfunction (E-CLAD)

Mrs Kimberly Schell (current)

Thesis: Extracellular Vesicle MicroRNA Profiles in relation to ECP-Response in Patients with GvHD

Mrs Kay Carruthers (current)

Thesis: Pancreatic islet cell isolation & characterisation for clinical use and identifying novel potency assays

Dr Sadaf Atarod (alumnus)

Dr Rihab Gam (alumnus)

MRes

Annual MRes students

BSc

Annual undergraduate students from BSc Biomedical Sciences

Other Teaching

COST Action 17138 chronic GvHD Short Term Scientific Mission Coordinator and Supervisor (Current)

Versus Arthritis Tissue Engineering Centre Training and Development Programme Coordinator (Previous)

• Articles

  • Al-Shaibani M, Wang X-N, Tulah A, Crossland RE, Dickinson AM, Lovat PE. Role of mesenchymal stem cell conditioned medium on wound healing using a developed 3D skin model. Journal of Wound Care 2024, 33, clxxxii-cxciii.
  • Scalzone A, Sanjurjo-Rodriguez C, Berlinguer-Palmini R, Dickinson AM, Jones E, Wang X-N, Crossland RE. Functional and Molecular Analysis of Human Osteoarthritic Chondrocytes Treated with Bone Marrow-Derived MSC-EVs. Bioengineering 2024, 11(4), 388.
  • Nihtila J, Salmenniemi U, Itala-Remes M, Crossland RE, Gallardo D, Bogunia-Kubik K, Lacina P, Bieniaszewska M, Giebel S, Hyvarinen K, Kekalainen E, Ritari J, Partanen J. Donor genetic determinant of thymopoiesis, rs2204985, and stem cell transplantation outcome in a multipopulation cohort. Human Immunology 2024, 85(3), 110791.
  • Rosenberger A, Crossland RE, Dressel R, Kube D, Wolff D, Wulf G, Bickeboller H, Dickinson A, Holler E. A genome-wide association study on hematopoietic stem cell transplantation reveals novel genomic loci associated with transplant outcomes. Frontiers in Immunology 2024, 15, 1280876.
  • Newman AM, Zaka M, Zhou P, Blain AE, Erhorn A, Barnard A, Crossland RE, Wilkinson S, Enshaei A, De Zordi J, Harding F, Taj M, Wood KM, Televantou D, Turner SD, Burke GAA, Harrison CJ, Bomken S, Bacon CM, Rand V. Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma. Leukemia 2022, 36(3), 781-789.
  • Crossland RE, Norden J, Ghimire S, Juric MK, Pearce KF, Lendrem C, Collin M, Mischak-Weissinger E, Holler E, Greinix HT, Dickinson AM. Profiling Tissue and Biofluid miR-155-5p,miR-155* and miR-146a-5p Expression in Graft vs Host Disease. Frontiers in Immunology 2021, 12, 639171.
  • Wielinska J, Crossland RE, Lacina P, Swierkot J, Bugaj B, Dickinson AM, Bogunia-Kubik K. Exploring the Extracellular Vesicle MicroRNA Expression Repertoire in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis Treated with TNF Inhibitors. Disease Markers 2021, 2021, 2924935.
  • Sanjurjo-Rodriguez C, Crossland RE, Reis M, Pandit H, Wang X-N, Jones E. Characterization and miRNA Profiling of Extracellular Vesicles from Human Osteoarthritic Subchondral Bone Multipotential Stromal Cells (MSCs). Stem Cells International 2021, 2021, 7232773.
  • Atarod S, Norden J, Bibby LA, Janin A, Ratajczak P, Lendrem C, Pearce KF, Wang XN, O'Reilly S, Van Laar JM, Collin M, Dickinson AM, Crossland RE. Differential MicroRNA Expression Levels in Cutaneous Acute Graft-versus-Host Disease. Frontiers in Immunology 2018, 9, 1485.
  • Ahmed FW, Bakhashab S, Bastaman IT, Crossland RE, Glanville M, Weaver JU. Anti-Angiogenic miR-222, miR-195, and miR-21a Plasma Levels in T1DM Are Improved by Metformin Therapy, Thus Elucidating Its Cardioprotective Effect: The MERIT Study. International Journal of Molecular Sciences 2018, 19(10), 3242.
  • Crossland RE, Norden J, Juric MK, Pearce KF, Lendrem C, Bibby LA, Collin M, Greinix HT, Dickinson AM. Serum and Extracellular Vesicle MicroRNAs miR-423, miR-199, and miR-93* As Biomarkers for Acute Graft-versus-Host Disease. Frontiers in Immunology 2017, 8, 1446.
  • Noble RA, Bell N, Blair H, Sikka A, Thomas H, Phillips N, Nakjang S, Miwa S, Crossland R, Rand V, Televantou D, Long A, Keun HC, Bacon CM, Bomken S, Critchlow SE, Wedge SR. Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and burkitt lymphoma. Haematologica 2017, 102(7), 1247-1257.
  • Crossland RE, Norden J, Juric MK, Green K, Pearce KF, Lendrem C, Greinix HT, Dickinson AM. Expression of Serum microRNAs is Altered During Acute Graft-versus-Host Disease. Frontiers in Immunology 2017, 8, 308.
  • Juric MK, Shevtsov M, Mozes P, Ogonek J, Crossland RE, Dickinson AM, Greinix HT, Holler E, Weissinger EM, Multhoff G. B-Cell-Based and Soluble Biomarkers in Body Liquids for Predicting Acute/Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Frontiers in Immunology 2017, 7, 660.
  • Jalapothu D, Boieri M, Crossland RE, Shah P, Butt IA, Norden J, Dressel R, Dickinson AM, Inngjerdingen M. Tissue-specific expression Patterns of Microrna during acute graft-versus-host Disease in the rat. Frontiers in Immunology 2016, 7, 361.
  • Crossland RE, Norden J, Bibby LA, Davis J, Dickinson AM. Evaluation of optimal extracellular vesicle small RNA isolation and qRT-PCR normalisation for serum and urine. Journal of Immunological Methods 2016, 429, 39-49.
  • Carey CD, Gusenleitner D, Chapuy B, Kovach AE, Kluk MJ, Sun HH, Crossland RE, Bacon CM, Rand V, Dal Cin P, Le LP, Neuberg D, Sohani AR, Shipp MA, Monti S, Rodig SJ. Molecular Classification of MYC-Driven B-Cell Lymphomas by Targeted Gene Expression Profiling of Fixed Biopsy Specimens. Journal of Molecular Diagnostics 2015, 17(1), 19-30.
  • Mazumdar R, Evans P, Culpin R, Bailey J, Allsup D. The automated monocyte count is independently predictive of overall survival from diagnosis in chronic lymphocytic leukemia and of survival following first-line chemotherapy. Leukemia Research 2013, 37(6), 614-618.
  • Culpin RE, Sieniawski M, Angus B, Menon GK, Proctor SJ, Milne P, McCabe K, Mainou-Fowler T. Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B-cell lymphoma patients. Histopathology 2013, 63(6), 788-801.
  • Culpin RE, Sieniawski M, Proctor SJ, Menon G, Mainou-Fowler T. MicroRNAs are suitable for assessment as biomarkers from formalin-fixed paraffin-embedded tissue, and miR-24 represents an appropriate reference microRNA for diffuse large B-cell lymphoma studies. Journal of Clinical Pathology 2013, 66(3), 249-252.
  • Culpin RE, Proctor SJ, Angus B, Crosier S, Anderson JJ, Mainou-Fowler T. A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines. International Journal of Oncology 2010, 37(2), 367-376.
  • Anderson JJ, Fordham S, Overman L, Dignum H, Wood K, Proctor SJ, Crosier S, Angus B, Culpin RE, Mainou-Fowler T. Immunophenotyping of diffuse large B-cell lymphoma (DLBCL) defines multiple sub-groups of germinal centre-like tumours displaying different survival characteristics. International Journal of Oncology 2009, 35(5), 961-971.
  • Culpin RE, Challen C, Wilkins B, Crosier S, Anderson JJ. Definitive identification of the Val617Phe mutation in myeloproliferative disorders using Real Time PCR utilising Roche Lightcycler/hybriprobe technology. 2007.

• Book Chapter

  • Crossland RE, Macdonald J, Wang X-N. Assessing MicroRNA Profiles from Low Concentration Extracellular Vesicle RNA Utilizing NanoString nCounter Technology. In: Astatke M, ed. RNA Amplification and Analysis. New York: Springer US, 2024, pp.101-123.

• Conference Proceedings (inc. Abstracts)

  • Newman AM, Zaka M, Zhou P, Erhorn A, Barnard A, Crossland RE, Wilkinson S, Wood K, Televantou D, Harrison CJ, Bomken S, Bacon CM, Rand V. Biallelic Inactivation of TP53 is Associated with an Increased Risk of Relapse in Paediatric B-Cell Non-Hodgkin Lymphoma(B-NHL). In: 50th Congress of the International Society of Paediatric Oncology (SIOP). 2019, Kyoto, Japan: John Wiley & Sons, Inc.
  • Zaka M, Crossland RC, Barnard A, Erhorn A, Wilkinson S, Bomken S, Bacon CM, Rand V. Integrated analysis of the genomic and microRNA landscapes identifies dysregulated pathways associated with relapsed paediatric B-cell Non-Hodgkin lymphoma. In: Sixth International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma. 2018, Rotterdam, Netherlands: British Journal of Haematology.
  • Newman AM, Zaka M, Zhou P, Erhorn A, Crossland RE, Wilkinson S, Enshaei A, Taj M, Wood K, Televantou D, Turner SD, Burke A, Harrison CJ, Bomken S, Bacon CM, Rand V. Biallelic inactivation of TP53 is associated with an increased risk of relapse in paediatric B-cell non-Hodgkin lymphoma (B-NHL). In: Sixth International Symposium on Childhood, Adolescent and Young Adult Non‐Hodgkin Lymphoma. 2018, Rotterdam, Netherlands: British Journal of Haematology.
  • Zhou P, Enshaei A, Newman AM, Chagaluka G, Lampert I, Van Noorden S, Erhorn A, Barnard A, Crossland RE, Wilkinson S, Nakang S, Moorman AV, Wood K, Televantou D, Carey P, Bomken S, Bacon CM, Bailey S, Molyneux E, Rand V. A Genomic Classification Model Enables Risk Stratification of Paediatric Endemic Burkitt Lymphona in Malawi. In: Abstracts from the 50th Congress of the International Society of Paediatric Oncology (SIOP). 2018, Kyoto, Japan: Pediatric Blood and Cancer.
  • Zhou P, Enshaei A, Newman AM, Banda K, Chagaluka G, Lampert I, Van Noorden S, Erhorn A, Barnard A, Crossland RE, Wilkinson S, Nakjang S, Moorman AV, Wood K, Televantou D, Carey P, Bomken S, Bacon CM, Bailey S, Molyneux E, Rand V. A genomic classification model enables risk stratification of paediatric endemic Burkitt lymphoma. In: Sixth International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma. 2018, Rotterdam, Netherlands: British Journal of Haematology.
  • Crossland RE, Norden J, Collin M, Dickinson A. Urinary MicroRNA Expression is Associated with Incidence and Severity of Graft Versus Host Disease. In: 41st Annual Meeting of the European Society for Blood and Marrow Transplantation. 2015, Istanbul, Turkey: Nature Publishing Group.
  • Crossland RE, Norden J, Bibby L, Collin M, Dickinson A. Serum MicroRNAs MiR-146a, MiR-199, MiR-93*and MiR-423 as Biomarkers for Graft Versus Host Disease. In: 41st Annual Meeting of the European Society for Blood and Marrow Transplantation. 2015, Istanbul, Turkey: Nature Publishing Group.
  • Gam R, Norden J, Crossland R, Pearce K, Holler E, Dressel R, Dickinson A. MICA genotype, serum and expression level effects on the outcome of HSCT. In: 41st Annual Meeting of the European Society for Blood and Marrow Transplantation. 2015, Istanbul, Turkey.
  • Gam R, Norden J, Crossland R, Pearce K, Holler E, Dressel R, Dickinson AM, Framework CellEurope Project, Professor Anne Dickinson Univ Newc. MICA genotype, serum and expression level effects on the outcome of HSCT. In: 41st Annual Meeting of the European Society for Blood and Marrow Transplantation. 2015, Istanbul, Turkey: Nature Publishing Group.
  • Gam R, Norden J, Crossland R, Pearce K, Dickinson A. IRAK1 and miR-146a for predicting the outcome of allogeneic haematopoietic stem cell transplantation. In: 41st Annual Meeting of the European Society for Blood and Marrow Transplantation. 2015, Istanbul, Turkey.
  • Gam R, Norden J, Crossland R, Pearce K, Dickinson AM, Univ Newcastle Upon Tyne. IRAK1 and miR-146a for predicting the outcome of allogeneic haematopoietic stem cell transplantation. In: 41st Annual Meeting of the European Society for Blood and Marrow Transplantation. 2015, Istanbul, Turkey: Nature Publishing Group.
  • Zhou P, Crossland R, Erhorn A, Rand V. High-resolution copy number analysis using low input, degraded DNA from fine-needle aspirates and macrodissected archival Burkitt lymphoma material. In: Fifth International Symposium on Childhood Adolescent and Young Adult Non-Hodgkin Lymphoma. 2015, Varese, Italy: British Journal of Haematology.
  • Zhou PX, Crossland R, Erhorn A, Rand V. High-resolution copy number analysis using low input, degraded DNA from fine-needle aspirates and macrodissected archival Burkitt lymphoma material. In: Fifth International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma. 2015, Varese, Italy: Wiley.
  • Crossland RE, Green K, Bacon C, Rand V. Direct digital profiling of multiplexed mRNA expression from degraded formalin fixed paraffin embedded aggressive paediatric B-cell lymphoma tumour tissue. In: Fifth International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma. 2015, Varese, Italy: Wiley.
  • Atarod S, Pearce K, Norden J, Lendrem C, Crossland R, Wang X, Sviland L, Janin A, Collin M, Dickinson A. Differential microRNA expressions in cutaneous acute graft-versus-host disease. In: 41st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT). 2015, Istanbul, Turkey.
  • Crossland RE, Norden J, Bibby L, Davis J, Dickinson AM. Validation of Isolation Methodology and Endogenous Control Selection for qRT-PCR Assessment of Microrna Expression in Serum and Urine Exosomes. In: 56th ASH Annual Meeting and Exposition. 2014, San Francisco, CA, USA: American Society of Hematology.
  • Crossland RE, Norden J, Collin M, Dickinson AM. Urinary Micrornas MiR-377, MiR-423, MiR-93 and MiR-199 As Biomarkers for Graft Versus Host Disease. In: 56th ASH Annual Meeting and Exposition. 2014, San Francisco, CA, USA: American Society of Hematology.
  • Rand V, Johnstone S, Crossland RE, Wilkinson S, Hall AG. The Genomic Landscape of Relapsed B-Cell Acute Lymphoblastic Leukaemia (B-ALL) in Adolescents and Adults. In: 56th ASH Annual Meeting and Exposition. 2014, San Francisco, CA: American Society of Hematology.
  • Crossland RE, Mainou-Fowler T, Sieniawski M, Bacon C, Rand V. High BACH2 gene Expression Is an Indicator of Poor Prognosis in Adult Diffuse Large B-Cell Lymphoma Treated with R-CHOP. In: 56th ASH Annual Meeting and Exposition. 2014, San Francisco, CA: American Society of Hematology.
  • Culpin R, Pearce K, Bailey J, Pointon J, Sunter N, Bailey J, Evans P, Allsup D, Allan J, Mainou-Fowler T. MicroRNAs in B-cell chronic lymphocytic leukaemia (B-CLL): mature microRNAs of the miR-17-92 cluster predict for treatment free survival (TFS) in patients with B-CLL. In: International Journal of Molecular Medicine. 2011, Spandidos Publications.
  • Culpin R, Sieniawski M, Anderson J, Angus B, Proctor S, Menon G, McCabe K, Milne P, Crosier S, Mainou-Fowler T. Mature microRNAs of the miR-17-92 cluster predict for disease outcome in diffuse large B-cell lymphoma (DLBCL) patients treated with CHOP-R immunochemotherapy. In: International Journal of Molecular Medicine. 2011, Spandidos Publications.
  • Culpin RE, Pearce K, Bailey JR, Sunter NJ, Pointon JC, Proctor SJ, Allsup DJ, Allan JM, Mainou-Fowler T. Mature MicroRNAs Mir-18,-19a,-19b,-17-5p and-92 of the Mir-17-92 Cluster Predict for Treatment Free Survival In Patients with Chronic Lymphocytic Leukaemia. In: Blood: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, Florida, USA: American Society of Hematology.
  • Culpin RE, Pearce K, Bailey JR, Sunter NJ, Pointon JC, Proctor SJ, Allsup DJ, Allan JM, Fowler TM. Mature MicroRNAs Mir 18, 19a, 19b, 17 5p and 92 of the Mir 17 92 Cluster Predict for Treatment Free Survival In Patients with Chronic Lymphocytic Leukaemia. In: Blood: 52nd Annual Meeting of the American Society of Hematology (ASH). 2010, Orlando, Florida, USA: American Society of Hematology.
  • Culpin RE, Anderson JJ, Angus B, Proctor SJ, Crosier S, Mainou-Fowler T. A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines. In: British Journal of Haematology: 50th Annual Scientific Meeting of the British Society for Haematology. 2010, Edinburgh, UK: Wiley-Blackwell Publishing Ltd.
  • Culpin RE, Anderson JJ, Angus B, Proctor SJ, Crosier S, Mainou-Fowler T. A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines. In: EJC Supplements: 21st Meeting of the European Association for Cancer Research. 2010, Oslo, Norway: Pergamon.

• Reviews

  • Bojanic I, Worel N, Pacini CP, Stary G, Piekarska A, Flinn AM, Schell KJ, Gennery AR, Knobler R, Lacerda JF, Greinix HT, Pulanic D, Crossland RE. Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers. Frontiers in Immunology 2023, 14, 1086006.
  • Gail LM, Schell KJ, Lacina P, Strobl J, Bolton SJ, Steinbakk Ulriksen E, Bogunia-Kubik K, Greinix H, Crossland RE, Inngjerdingen M, Stary G. Complex interactions of cellular players in chronic Graft-versus-Host Disease. Frontiers in Immunology 2023, 14, 1199422.
  • Doglio M, Crossland RE, Alho AC, Penack O, Dickinson AM, Stary G, Lacerda JF, Eissner G, Inngjerdingen M. Cell-based therapy in prophylaxis and treatment of chronic graft-versus-host disease. Frontiers in Immunology 2022, 13, 1045168.
  • Partanen J, Hyvarinen K, Bickeboller H, Bogunia-Kubik K, Crossland RE, Ivanova M, Perutelli F, Dressel R. Review of Genetic Variation as a Predictive Biomarker for Chronic Graft-Versus-Host-Disease After Allogeneic Stem Cell Transplantation. Frontiers in Immunology 2020, 11, 575492.
  • Crossland RE, Perutelli F, Bogunia-Kubik K, Mooney N, Milutin Gasperov N, Pucic-Bakovic M, Greinix H, Weber D, Holler E, Pulanic D, Wolff D, Dickinson AM, Inngjerdingen M, Grce M. Potential Novel Biomarkers in Chronic Graft-Versus-Host Disease. Frontiers in Immunology 2020, 11, 602547.
  • Gam R, Shah P, Crossland RE, Norden J, Dickinson AM, Dressel R. Genetic Association of Hematopoietic Stem Cell Transplantation Outcome beyond Histocompatibility Genes. Frontiers in Immunology 2017, 8, 380.